Informations générales (source: ClinicalTrials.gov)
Assessment of HGI (Hemoglobin Glycation Index) Variability Over Time in Patients Living With Diabetes Using Continuous Glucose Monitoring
Interventional
N/A
Nantes University Hospital (Voir sur ClinicalTrials)
juin 2024
septembre 2028
13 mai 2026
The goal of this clinical trial is to learn about the variability of HGI (Hemoglobin
Glycation Index) over time in patients living with diabetes using a continuous glucose
monitoring.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL NOVO | CAMPINOS Catherine | 18/09/2025 17:50:07 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| HOPITAL NOVO | Contact (sur clinicalTrials) | ||||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU de Nantes - 44093 - Nantes - France | Contact (sur clinicalTrials) | ||||
| CHU de Poitiers - 86021 - Poitiers - France | Contact (sur clinicalTrials) | ||||
| CHU de Rennes - 35000 - Rennes - France | Contact (sur clinicalTrials) | ||||
| CHU de Toulouse - 31059 - Toulouse - France | Contact (sur clinicalTrials) | ||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CH du Mans - 72037 - Le Mans - France | Contact (sur clinicalTrials) | ||||
| CHU d'Angers - 49100 - Angers - France | Contact (sur clinicalTrials) | ||||
| CHU de Brest - 29200 - Brest - France | Contact (sur clinicalTrials) | ||||
| CHU de Caen - 14033 - Caen - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
- Major (adult subject over 18), with no upper age limit
- Enrolled in a social security scheme or beneficiary of such a scheme
- Agreement to participate (informed, written consent)
- Established diabetes (regardless the type of diabetes), known for at least 6 months
at inclusion
- Regular user of a glucose monitoring system for at least 3 months.
Non inclusion Criteria:
- Known hemoglobinopathy
- Inadequate use of the flash glucose monitoring system with a capture rate of less
than 70% of interstitial glucose measurements, during the 3 months preceding the
inclusion visit.
- Stage 5 renal insufficiency (CKD-EPI less than 15 mL/min/1.73 m2)
- Pregnant or breast-feeding
- Major under guardianship, curatorship or safeguard of justice
- Any situation assessed by the investigator as potentially prejudicial to the
participant's health as a result of participation in the study
Exclusion criteria:
- Treatment with corticosteroids in the 3 months preceding the visit
- Unusual acute situation (infection, very unusual physical activity, etc.) deemed
significant by the investigator
- Pregnancy started